First drug utilization data related to an anticholinergic agent recently marketed in Italy

A retrospective drug utilisation study was conducted, concerning a new bronchodilator (tiotropium, ATC code: R03BB04) in the first six months after its launch in Italy. The source of data was the administrative database run by a Local Health Unit located in Northern Italy. All patients (920) were se...

Full description

Bibliographic Details
Main Authors: Carlo Lucioni, S. Mazzi, C. Cerra, S. Lottaroli
Format: Article
Language:English
Published: SEEd Medical Publishers 2006-09-01
Series:Farmeconomia: Health Economics and Therapeutic Pathways
Subjects:
Online Access:https://journals.seedmedicalpublishers.com/index.php/FE/article/view/264
id doaj-443a05c8f33340f898ccd964a2ef5e63
record_format Article
spelling doaj-443a05c8f33340f898ccd964a2ef5e632020-11-25T01:57:43ZengSEEd Medical PublishersFarmeconomia: Health Economics and Therapeutic Pathways2240-256X2006-09-017318719210.7175/fe.v7i3.264239First drug utilization data related to an anticholinergic agent recently marketed in ItalyCarlo Lucioni0S. Mazzi1C. Cerra2S. Lottaroli3Wolters Kluwer Health/ADIS International, MilanoWolters Kluwer Health/ADIS International, MilanoServizio Informativo e Controllo Gestione, A.S.L. PaviaServizio Informativo e Controllo Gestione, A.S.L. PaviaA retrospective drug utilisation study was conducted, concerning a new bronchodilator (tiotropium, ATC code: R03BB04) in the first six months after its launch in Italy. The source of data was the administrative database run by a Local Health Unit located in Northern Italy. All patients (920) were selected with at least one prescription for tiotropium between September and December 2004, and data about their use of health resources (hospitalisations, class ATC R03 drugs, lab tests – only drugs and test prescribed in outpatient setting) was collected. Starting from such initial sample, further sub-samples were created (in particular to focus on patients affected by COPD – Chronic Obstructive Pulmonary Disease, for which tiotropium has got the therapeutic indication by the Italian Health Service), for the purpose of different levels of analysis. Results reported in this abstract are referred to the first level (702 patients, aged 40 years or more, still living at the end of the observation period, already with COPD in the previous year); they are expressed as average data per patient on a six-month period. Prescriptions of R03 drugs were 7.8, including 2.4 specifically for tiotropium. To such prescriptions, 348 and 103 DDDs (Defined Daily Doses) respectively corresponded; and, analogously, a cost of 487 and 205 euros. The cost for hospitalisations was 525 euros and the cost for lab tests was 28.5 euros. The other analysis levels (sub-samples with fewer patients) produced not very different outcomes. Evidence given here should prove the potential interest of such kind of studies.https://journals.seedmedicalpublishers.com/index.php/FE/article/view/264tiotropiumdrug utilisationadministrative databasescopditaly
collection DOAJ
language English
format Article
sources DOAJ
author Carlo Lucioni
S. Mazzi
C. Cerra
S. Lottaroli
spellingShingle Carlo Lucioni
S. Mazzi
C. Cerra
S. Lottaroli
First drug utilization data related to an anticholinergic agent recently marketed in Italy
Farmeconomia: Health Economics and Therapeutic Pathways
tiotropium
drug utilisation
administrative databases
copd
italy
author_facet Carlo Lucioni
S. Mazzi
C. Cerra
S. Lottaroli
author_sort Carlo Lucioni
title First drug utilization data related to an anticholinergic agent recently marketed in Italy
title_short First drug utilization data related to an anticholinergic agent recently marketed in Italy
title_full First drug utilization data related to an anticholinergic agent recently marketed in Italy
title_fullStr First drug utilization data related to an anticholinergic agent recently marketed in Italy
title_full_unstemmed First drug utilization data related to an anticholinergic agent recently marketed in Italy
title_sort first drug utilization data related to an anticholinergic agent recently marketed in italy
publisher SEEd Medical Publishers
series Farmeconomia: Health Economics and Therapeutic Pathways
issn 2240-256X
publishDate 2006-09-01
description A retrospective drug utilisation study was conducted, concerning a new bronchodilator (tiotropium, ATC code: R03BB04) in the first six months after its launch in Italy. The source of data was the administrative database run by a Local Health Unit located in Northern Italy. All patients (920) were selected with at least one prescription for tiotropium between September and December 2004, and data about their use of health resources (hospitalisations, class ATC R03 drugs, lab tests – only drugs and test prescribed in outpatient setting) was collected. Starting from such initial sample, further sub-samples were created (in particular to focus on patients affected by COPD – Chronic Obstructive Pulmonary Disease, for which tiotropium has got the therapeutic indication by the Italian Health Service), for the purpose of different levels of analysis. Results reported in this abstract are referred to the first level (702 patients, aged 40 years or more, still living at the end of the observation period, already with COPD in the previous year); they are expressed as average data per patient on a six-month period. Prescriptions of R03 drugs were 7.8, including 2.4 specifically for tiotropium. To such prescriptions, 348 and 103 DDDs (Defined Daily Doses) respectively corresponded; and, analogously, a cost of 487 and 205 euros. The cost for hospitalisations was 525 euros and the cost for lab tests was 28.5 euros. The other analysis levels (sub-samples with fewer patients) produced not very different outcomes. Evidence given here should prove the potential interest of such kind of studies.
topic tiotropium
drug utilisation
administrative databases
copd
italy
url https://journals.seedmedicalpublishers.com/index.php/FE/article/view/264
work_keys_str_mv AT carlolucioni firstdrugutilizationdatarelatedtoananticholinergicagentrecentlymarketedinitaly
AT smazzi firstdrugutilizationdatarelatedtoananticholinergicagentrecentlymarketedinitaly
AT ccerra firstdrugutilizationdatarelatedtoananticholinergicagentrecentlymarketedinitaly
AT slottaroli firstdrugutilizationdatarelatedtoananticholinergicagentrecentlymarketedinitaly
_version_ 1724972998462537728